Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorBy Jeffrey Neal Johnson. Originally Published: 2/24/2026. 
What You Need to Know - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
While the technology sector faces another wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different picture is emerging in the healthcare sector. Investors fleeing the jittery swings of high-growth tech names are finding shelter in a familiar company that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of about $245 per share, creating a divergence that's drawing Wall Street attention. This rally runs counter to the perception of the healthcare giant as a slow-moving, "boring" stock. Over the past 30 days, shares have climbed roughly 14%, significantly outpacing the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and paying up for stability, dependable cash flow, and strong execution. For investors watching the ticker on Feb. 24, 2026, it's important to note a calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely fall by the upcoming dividend amount, $1.30 per share, as a mechanical market adjustment — not a reflection of business performance. For income-focused investors, that technical dip often presents an attractive entry point rather than a reason to sell. 64 Years of Unbroken Growth The core argument for holding Johnson & Johnson through turbulent markets is its financial stability and role as a portfolio stabilizer. The company is part of an elite group known as Dividend Kings: firms that have raised their dividend for at least 50 consecutive years. Johnson & Johnson has increased its dividend for 64 consecutive years, a record that spans multiple recessions, market crashes, and geopolitical shocks. That consistency is rare in a market often focused on speculative growth. The stock currently yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in the bond market or riskier sectors, J&J's appeal lies in the blend of income and safety. Management projects free cash flow near $21 billion in 2026, a cushion that supports dividends, R&D investment, and legal costs without heavy borrowing. For risk-averse investors, another compelling metric is the stock's Beta, which measures how much a security moves relative to the overall market (S&P 500). A Beta of 1.0 means movement in lockstep with the market. Johnson & Johnson's Beta is about 0.35, implying the stock is historically roughly 65% less volatile than the broader market. When tech names swing wildly, J&J tends to hold its ground, making it a useful volatility dampener in technology-heavy portfolios. Beyond the Patent Cliff: The Road to $100 Billion Safe stocks are often assumed to lack growth, but Johnson & Johnson is challenging that view with a strategic pivot that appears to be paying off. Management has issued strong guidance for 2026, forecasting full-year revenue above the $100 billion mark for the first time in company history, along with adjusted earnings per share around $11.53. That growth is driven by the reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors had worried about a patent cliff after Stelara, a blockbuster immunology drug, lost exclusivity in 2025. Rather than seeing a revenue collapse, J&J has offset that decline with the rise of new blockbusters. Two key assets are driving this resilience: - Darzalex: An oncology leader generating roughly $14 billion in annual sales. It has become a cornerstone therapy in multiple myeloma treatment worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya has reported strong three-year remission data for ulcerative colitis, helping the company retain share in a competitive immunology market.
The Tech in MedTech: High-Margin Technologies The growth narrative extends into the MedTech division, which has shifted focus toward higher-growth, higher-margin technologies. A notable example is the integration of Shockwave Medical, acquired to modernize J&J's cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) uses sonic pressure waves to break up calcified plaque in arteries — conceptually similar to kidney stone treatments — and represents a substantial improvement over traditional angioplasty balloons. Owning this technology gives Johnson & Johnson a high-growth product that complements its cardiac devices and surgical businesses. J&J is also advancing in surgical robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft-tissue robotics market. These high-tech devices typically command higher profit margins and create sticky relationships with hospital systems, offering a long-term earnings tailwind beyond basic supplies. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate footprint. A key development is the potential separation or mega sale of the DePuy Synthes orthopedics business, originally contemplated as a spin-off. Divesting the orthopedics unit is an "addition by subtraction" move: orthopedics is relatively mature and slower-growing compared with the booming fields of oncology and cardiac devices. Selling the unit would likely boost J&J's organic revenue growth and margins, while generating a large one-time cash inflow that could be used for acquisitions or share buybacks. Legal risks remain an important consideration. The company faces ongoing talc litigation, with a recent $1.5 billion verdict keeping the issue in the headlines, and a commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has added noise. Still, the market's recent rally suggests investors are looking beyond these headlines. Bulls argue that Johnson & Johnson has the financial resources to handle liabilities without disrupting operations. With over $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and projected free cash flow near $21 billion, the company is well-positioned to absorb settlements — keeping legal matters on the balance sheet rather than threatening the dividend or core business. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. After spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, J&J is concentrating on higher-growth opportunities in pharmaceuticals and medical technology. Although the stock trades near all-time highs and is no longer a bargain, it offers a blend of capital preservation and growth that's hard to find elsewhere. The combination of a 64-year dividend growth streak, a low volatility profile, and a credible path to $100 billion in revenue makes Johnson & Johnson an appealing option for 2026. For investors fatigued by the unpredictability of the technology sector, J&J demonstrates that, in the current market, being "boring" can be both beautiful and profitable.
| 
